Category «orphan drug»

Tagraxofusp タグラクソフスプ

It’s only fair to share… MGADDVVDSS KSFVMENFSS YHGTKPGYVD SIQKGIQKPK SGTQGNYDDD WKGFYSTDNK YDAAGYSVDN ENPLSGKAGG VVKVTYPGLT KVLALKVDNA ETIKKELGLS LTEPLMEQVG TEEFIKRFGD GASRVVLSLP FAEGSSSVEY INNWEQAKAL SVELEINFET RGKRGQDAMY EYMAQACAGN RVRRSVGSSL SCINLDWDVI RDKTKTKIES LKEHGPIKNK MSESPNKTVS EEKAKQYLEE FHQTALEHPE LSELKTVTGT NPVFAGANYA AWAVNVAQVI DSETADNLEK TTAALSILPG IGSVMGIADG AVHHNTEEIV AQSIALSSLM VAQAIPLVGE LVDIGFAAYN FVESIINLFQ VVHNSYNRPA YSPGHKTRPH MAPMTQTTSL KTSWVNCSNM IDEIITHLKQ PPLPLLDFNN LNGEDQDILM ENNLRRPNLE AFNRAVKSLQ NASAIESILK NLLPCLPLAT AAPTRHPIHI KDGDWNEFRR …

Caplacizumab, カプラシズマブ Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder

It’s only fair to share… Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder On September 03, 2018, the European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is …

Icosapent ethyl, イコサペント酸エチル

It’s only fair to share… Icosapent ethyl 330.5042 , C22H34O2 cas 86227-47-6 / 73310-10-8 ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate Ethyl eicosapentaenoic acid イコサペント酸エチル (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)- [ACD/Index Name] 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- 6GC8A4PAYH 86227-47-6 [RN] all-cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester Timnodonic acid ethyl ester Vascepa 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl …

Tasimelteon, タシメルテオン

It’s only fair to share… Tasimelteon N-([(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide, 609799-22-6 [RN] 8985 Hetlioz [Trade name] N-{[(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide [ACD/IUPAC Name] Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]- [ACD/Index Name] SHS4PU80D9 609799-22-6 cas, BMS-214778; VEC-162, ATC:N05CH03 Use:Treatment of sleep disorder; Melatonin receptor agonist (1R,2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide Formula:C15H19NO2, MW:245.3 g/mol Hetlioz Vanda Pharmaceuticals, 2014 Approved fda 2014 EMA Tasimelteon is a white to off-white crystalline powder, it is non hygroscopic, soluble in water across relevant …

FDA approves first drug Oxervate (cenegermin) for neurotrophic keratitis, a rare eye disease

It’s only fair to share… http://www.who.int/medicines/publications/druginformation/issues/77_INN_Recommended_List.pdf Active Substance General information The active substance in Oxervate, cenegermin, is a recombinant human Nerve Growth factor (rhNGF) produced in E. coli strain HMS174. The molecule is identical to human Nerve Growth factor (NGF), a naturally occurring human protein. In humans, NGF is naturally produced as pre-pro-peptide, secreted into …

Patisiran

It’s only fair to share… Patisiran Sense strand: GUAACCAAGAGUAUUCCAUdTdT Anti-sense strand: AUGGAAUACUCUUGGUUACdTdT RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1), ALN-18328, 6024128  , ALN-TTR02  , GENZ-438027  , SAR-438037  , 50FKX8CB2Y (UNII code)  for RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) Nucleic Acid Sequence Sequence Length: 42, 21, 2112 a 7 c 7 g 4 t 12 umultistranded (2); modified CAS 1420706-45-1 Treatment of Amyloidosis, …

Vatiquinone, バチキノン

It’s only fair to share… Vatiquinone バチキノン Vatiquinone; Alpha-Tocotrienol quinone; EPI-743; UNII-6O85FK9I0X; 1213269-98-7; Vincerenone Molecular Formula: C29H44O3 Molecular Weight: 440.668 g/mol 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 2-((R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 6O85FK9I0X 9604 Research Code:EPI-743; ATQ-3, BioE-743 MOA:Mitochondria Originator Edison Pharmaceuticals Developer Edison Pharmaceuticals; Sumitomo Dainippon Pharma; University of Florida; Yale University Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules Mechanism of Action Antioxidants; NQO1 modulators Orphan Drug Status Yes – Mitochondrial …

FDA approves first treatment Azedra (iobenguane I 131) for rare adrenal tumors

It’s only fair to share…   Iobenguane I 131   FDA approves first treatment for rare adrenal tumors The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) …

TAFENOQUINE, タフェノキン

It’s only fair to share… Tafenoquine タフェノキン N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- 106635-80-7 [RN] 262P8GS9L9 7835 N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluormethyl)phenoxy]-8-chinolinyl}-1,4-pentandiamin WR-238605, WR 238605, cas no 106635-80-7, Tafenoquine succinate, Etaquine, SB-252263, WR-238605 N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine Molecular Formula: C24H28F3N3O3 Molecular Weight: 463.49263 Medicines for Malaria Venture Walter Reed Army Institute (Originator) PATENT  US 4617394 Synonyms Etaquine[5] WR 238605 [5] SB-252263 New Drug Application (NDA): 210795 Company: GLAXOSMITHKLINE FDA approved on July 20, 2018 FDA …

Ivosidenib,  ивосидениб , إيفوزيدينيب , 艾伏尼布 , 

It’s only fair to share… Ivosidenib AG-120; TIBSOVO FDA approves first targeted treatment Tibsovo (ivosidenib) for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) …